SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Landipirdine (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms SYNAPSE
- Sponsors Biotie Therapies Corp.
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 09 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.